FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Bid/Ask 15:47:26 2024-06-20 EDT | ||
| 43.2 EUR | +3.52% |
|
| Current month | +9.66% | ||
| 1 month | +15.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 43.2 | +3.52% |
| 24-06-19 | 41.73 | -0.33% |
| 24-06-18 | 41.87 | -5.83% |
| 24-06-17 | 44.46 | -4.82% |
| 24-06-14 | 46.71 | +8.45% |
Real-time Boerse Frankfurt Warrants
Last update June 20, 2024 at 03:47 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU9AVA |
| ISIN | DE000SU9AVA0 |
| Date issued | 2024-02-14 |
| Strike | 9,550 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 51.13 € |
|---|---|
| Lowest since issue | 9.87 € |
| Spread | 2.91 € |
| Spread % | 6.27% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Certificates
- Certificat
